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 PENJERAPAN UREA DAN ASID URIK OLEH  
BAHAN BIO BERLIANG NANO  
 
ABSTRAK 
 
 Kelemahan hemodialisis zaman ini telah menjadi punca penyelidikan dan 
pembangunan beberapa prototaip ginjal buatan mudah alih. Komponen utama model 
mudah alih ini (berbanding hemodialisis) ialah sistem dialisat tertutup. Secara 
tipikalnya, model-model ini biasanya menggunakan karbon teraktif sebagai bahan 
penjerap. Penggunaan bahan penjerap yang lebih unggul, jumlah dialisat yang 
diperlukan untuk penyingkiran toksin uremik boleh dikurangkan dan dikitar semula. 
Motivasi utama bagi penyelidikan ini ialah kekurangan pemilihan bahan untuk bahan 
penjerap dalam model-model ini. Oleh itu, objektif projek ini ialah sintesis dan 
penilaian tiga jenis biobahan berliang nano yang baru, iaitu gentian karbon teraktif 
berongga (ACF), silika berliang meso (MS) dan hidroksiapatit berliang meso, dengan 
sasaran untuk penyingkiran konstituen utama toksin uremik, iaitu urea dan asid urik. 
ACF telah diperolehi melalui kaedah pengaktifan asid dengan menggunakan asid-
asid yang berbeza; asid bukan organic sulfurik, nitrik dan fosforik; asid organik 
asetik dan sitrik. MS dan HAp telah disintesis melalui kaedah templat lembut dengan 
surfaktan Pluronics. Keputusan awal penjerapan urea telah menunjukkan bahawa MS 
dengan kumpulan berfungsi amina dan ACF terawat asid sulfuric adalah sangat baik 
(550 mg/g) berbanding dengan karbon teraktif komersil (CAC). Ujian kinetik 
penjerapan urea telah mendedahkan mekanisma penjerapan urea oleh ACF (jerapan 
fizikal) dan MS (jerapan kimia). MS amina dan diamina menjerap lebih daripada 30 
molekul per nm
2
 (jerapan kimia yang kuat) berbanding MS biasa, CAC dan pelbagai 
xv 
 
ACF, yang telah menjerap kurang daripada 10 molekul per nm
2
 (jerapan fizikal). 
Faktor-faktor utama yang mempengaruhi kapasiti jerapan ialah keliangan dan kimia 
permukaan yang sesuai, yang mana kedua-duanya dipunyai oleh MS amina dan 
diamina. Kebolehubahan permukaan berfungsi bagi MS merupakan asas untuk ujian 
jerapan urik asid seterusnya. Satu hipotesis peningkatan jerapan asid urik oleh MS 
terfungsi amina merupakan melalui tindak balas kimia asid-amina. Jerapan asid urik 
oleh MS tidak mengikut keluk jerapan teori. Analisa yang mendalam dengan 
menggunakan aplikasi MATLAB menunjukkan bahawa MS telah menjalani jerapan 
dan nyahrepan serentak, dengan kadar jerapan permulaan setinggi 20.3 mg/g/s 
berbanding gel silica dengan kadar jerapan hanya 0.39 mg/g/s. Sebagai kesimpulan, 
secara keseluruhannya, keputusan jerapan urea dan asid urik MS dan ACF lebih baik 
berbanding CAC dan gel silika komersil.  
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UREA AND URIC ACID ADSORPTION BY NANOPOROUS 
BIOMATERIALS  
ABSTRACT 
 The limitations of the present hemodialysis have led towards the research and 
development of several wearable artificial kidney prototypes. The most important 
component of the miniaturised model is the closed-system dialysate, achieved 
through the utilisation of solid activated carbon as adsorbents. With the application 
of superior alternative adsorbents, the amount of dialysate required could be reduced 
due to efficient regeneration. The main motivation for this project is the lack of 
adsorbent materials selection. Thus, this project aims to synthesise and evaluate three 
emerging nanoporous biomaterials, i.e. hollow activated carbon fibre (ACF), 
mesoporous silica (MS) and mesoporous hydroxyapatite (HAp), targeting major 
uremic toxin constituent urea and uric acid. ACF was obtained though the acid 
activation route, with variation in acid used; inorganic acids sulphuric, nitric and 
phosphoric; organic acids acetic and citric. MS and HAp was synthesised through 
soft templating route using Pluronics surfactant. Results show that amine 
functionalised MS and sulphuric acid treated ACF performed well in the preliminary 
urea adsorption capacity evaluation (550 mg/g), as compared to the control 
commercial activated carbon (CAC) (350 mg/g). Subsequent urea kinetics study 
revealed better understanding of urea adsorption mechanism by ACF and MS, 
whereby ACF and MS operate through physisorption and chemisorption 
respectively. Amine and diamine MS adsorbed more than 30 molecules per nm
2
 
(strong chemisorption interaction) compared to bare MS, CAC and various ACF, 
which adsorbed less than 10 molecules per nm
2
 (physisorption). The most important 
factors which govern adsorption capacity are porosity and suitable surface chemistry, 
xvii 
 
both which are possessed by amine and diamine MS. The flexibility of surface 
functionalisation of MS is the basis of subsequent uric acid adsorption kinetics test. 
Amine functionalised MS is hypothesised to improve uric acid adsorption through 
acid-amine reaction. Uric acid adsorption by MS did not follow theoretical 
adsorption curve. Further analysis using MATLAB curve fit revealed that MS 
underwent simultaneous adsorption-desorption, with initial adsorption rates as high 
as 20.3 mg/g/s compared to commercial silica gel, with initial adsorption rate of 0.39 
mg/g/s. As a conclusion, on a whole, MS and ACF performed better than the 
benchmarked CAC and commercial silica gel in terms of urea and uric acid 
adsorption. 
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1. CHAPTER 1: INTRODUCTION 
 
1.1 Research Background 
 Currently, the commonly accepted treatment for patients’ who suffer from 
kidney failure is hemodialysis. Nevertheless, due to the size of hemodialysis 
machines, patients would have to endure mobility restraint. Kidney transplant is by 
far the most ideal renal replacement treatment option but the number of patients 
usually greatly outnumbers the donors. The limited supply of available kidneys is the 
main reason kidney transplants are close to impossible, not to mention the donor-
patient compatibility of the organ which reduces the chance for a patient to accept 
the treatment. Peritoneal dialysis is a smaller renal replacement setup using the 
patient's peritoneum in the abdomen as a membrane for dialysis, which offers better 
mobility and flexibility for uremic toxin removal. However, the patients are faced 
with risks for future complications, such as infection in the peritoneum. Patients 
undergoing peritoneal dialysis have better mobility as compared to hemodialysis 
(Diaz‐Buxo et al., 1981; Olcott IV et al., 1983; Kooman et al., 2015). Though 
peritoneal dialysis shows better survival rates during initial stages of dialysis, the 
survival rates drop significantly over a longer treatment period compared to 
hemodialysis. Complications such as infection or peritonitis ultimately highlight 
hemodialysis as a better option (Sinnakirouchenan and Holley, 2011). Thus, despite 
all the disadvantages, hemodialysis still remains the most feasible option in terms of 
safety, cost and treatment efficiency. 
 The current hemodialysis setup which uses diffusion-based membrane 
technology is not efficient since uremic toxins with high molecular mass could not be 
removed (Vanholder et al., 2003). The residual uremic toxins which were not 
2 
 
removed would gradually build up in the patients’ body. The retention of uremic 
toxin similar to a slow and gradual poisoning (uremia). Eventually, life span is 
shortened as the suffering period is prolonged. Each individual uremic toxin build-up 
in a chronic kidney disease (CKD) patient would cause its own complications. For 
instance, uric acid retention would cause serious problems such as gout, diabetes and 
leukemia (Kang, 2014). Present hemodialysis is not a perfect solution; the period of 
initial uremic toxin poisoning leading up until the upper concentration threshold 
which the human body could withstand, is merely prolonged. One other inherent 
problem of hemodialysis is that it is not a continuous uremic toxin removal process. 
High and low uremic toxin cyclic levels during treatment and non-treatment periods 
would cause a state of shock on a patient's body (Figure 1.1). 
 
Figure 1.1: Uremic toxin retention cycle pre- and during hemodialysis  
 
 Furthermore, the mobility of patients is hindered due to their dependency on 
hemodialysis. Patients would have to travel to hemodialysis centres for treatment on 
alternate days during a week (3 times), and undergo hemodialysis treatment for 4 
hours during each session, excluding travel (Dhondt et al., 2000). Patients would face 
difficulty in their job commitments due to constant absence from work during 
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treatment periods. Patients without a flexible working hour job might lose their 
source of income once the long-term treatment begins, which would directly cause 
the country to lose its workforce. They would not only become a liability to the 
country, but also a long-term financial burden for themselves and to the national 
healthcare system. In 2013, the total number of end stage renal disease (ESRD) 
patients in Malaysia amounts to 26,159 and is estimated to increase 4,000 yearly. 
Statistically, 14 out of 100,000 people suffers from kidney failure (Cheng, 2013).  
 The dialysis process itself is a long-term painful and expensive process, not 
only does CKD cause physically difficulty, but also mental stress. Hemodialysis 
takes a serious toll on patients, as side effects include shortness of breath, nausea and 
vomiting (Cukor et al., 2013; Vasilopoulou et al., 2015). Patients are also prone to 
mental side effects as depression since most of them have to make drastic changes in 
their home or work life and even to the extent of giving up certain responsibilities or 
activities. Patients no longer have the ability being away from designated dialysis 
centres, let alone the luxury to travel. Due to its bulky size and imperfect uremic 
toxin removal, hemodialysis is merely a life support once a patient's kidneys lose 
their functionality.  
 In the recent decade, wearable artificial kidney models (based on present 
hemodialysis design) are developed to solve the shortcomings of hemodialysis. At 
present, the frontrunner model developed by Gura and co-workers are undergoing 
clinical trials since early 2010 (Gura et al., 2009; Gura and Rambod, 2010; 
Davenport, 2015). However, the Gura prototype is still under research and mainly 
utilises ordinary activated carbon as the adsorbent. These miniaturised models are 
made possible due to the key component designed in these models, i.e. dialysate 
regenerative system. The bulk amount of dialysate fluid is regenerated using only 
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activated carbon as a solid sorbent. Without a deep understanding of biomaterials 
engineering and adsorbent–adsorbate chemistry, the load/capacity, efficiency and 
effectiveness of the mentioned prototype is limited and rigid, i.e. degree of 
miniaturisation is inhibited by the adsorbent design. 
 
1.2 Problem Statement 
 Firstly, the limitations of the conventional hemodialysis, based on brief 
literature covered in the previous section (Section 1.1 Research Background), i.e. 
bulky device which hinders patient mobility, could be overcome by the introduction 
of wearable artificial kidney models. Table 1.1 shows the comparison between the 
hemodialysis and an ideal artificial kidney. Hemodialysis based wearable artificial 
kidney systems are still at clinical trial stages at best. The introduction of nanoporous 
adsorbent in the form of activated carbon could effectively reduce the amount of 
dialysate fluid through active and continuous adsorption of uremic toxins from the 
dialysate fluid.  
 
Table 1.1: Hemodialysis and ideal artificial kidney 
Hemodialysis Ideal artificial kidney 
Intermittent Continuous 
Retention of middle molecules 
Indiscriminate removal of uremic toxins 
Retention of protein bound uremic toxins 
Bulky 
Portable 
Light weight 
 
 Secondly, the materials selection for the choice of adsorbent used for 
dialysate regeneration has been limited to only activated carbons, as evidently 
employed in all reviewed patents. The only alternative nanoporous adsorbent studied, 
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aside from activated carbon (Gura et al., 2009), is zeolite (Wernert et al., 2006; 
Wernert et al., 2005). These reports indicate that zeolite is better suited for the 
adsorption of middle molecules such as creatinine and p-cresol. The uremic toxins 
targeted in this study are urea and uric acid, which belong to the uremic toxin group 
of small molecules. The study on alternative nanoporous biomaterials which could 
produce better uremic toxin adsorption results would be highly valuable as the 
wearable artificial kidney models could be further miniaturised through reduced 
dialysate amount used in such systems. The amount of adsorbent materials for the 
dialysate regenerative system could also be reduced, thus a significant reduction in 
size and weight of the wearable device. The indication on the adsorption 
performance of a material used in this project is the mass of uremic toxin removed by 
a fixed amount of adsorbent, expressed in the form of mg/g. A higher number in such 
case would indicate more uremic toxin removed by the same amount of adsorbent. 
Apart from scalability size-wise, the duration of use for these higher adsorption 
nanoporous materials could be extended, i.e. the frequency of change of adsorbent 
materials (in cartridge form) is prolonged for the same amount of material. This 
project is focused on the development of improved alternative nanoporous 
adsorbents, i.e hollow activated carbon fibre, mesoporous silica and mesoporous 
hydroxyapatite, for the intended application of uremic toxin adsorption for wearable 
artificial kidney systems. Each of the three nanoporous biomaterials were selected 
based on the individual improvements in terms of physical properties (surface area) 
and chemical functionality (surface functional group and biocompatibility).  
Hollow activated carbon fibre was selected as an alternative nanoporous 
adsorbent material due to its higher surface area and shorter diffusion length. The 
hollow macropore channels enables shorter access of flowing adsorbates into the 
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micropores of this activated carbon, i.e. better adsorption kinetics (Bandosz, 2006). 
Access to micropores for conventional powdered or granular activated carbon are 
more restricted in comparison due to the lack of macropore (only mesopores). 
Mesoporous silica on the other hand, was selected due to the fact that the flexibility 
of surface functionalisation (Matsumoto et al., 2006). Active functional groups could 
be grafted and anchored on the surface of mesoporous silica to selectively target 
identified functional groups of uremic toxins urea (amine group) and uric acid 
(carbonyl group). The third nanoporous biomaterial, mesoporous hydroxyapatite, 
was selected due to its excellent biocompatibility (Akao et al., 1981; Selvakumar et 
al., 2015) and good protein adsorption (Shen et al., 2008).  
 
1.3 Research Objectives 
The purpose of this research is to explore potential alternative biomaterials for 
uremic toxin adsorption. Material selection for this application is limited to activated 
carbon as the sole adsorbent on this list. Research objectives for this project are: 
1. To synthesise and characterise three nanoporous biomaterials, i.e. activated 
carbon fibre, mesoporous silica and mesopores hydroxyapatite for urea and 
uric acid adsorption.  
2. To evaluate the urea adsorption capacity of activated carbon fibre, 
mesoporous silica and mesopores hydroxyapatite.  
3. To study the kinetics and mechanisms of urea and uric acid adsorption by 
activated carbon fibre, mesoporous silica and mesopores hydroxyapatite.  
 
